4.4 Article

Incidence and risk factors for hypoglycemia during maintenance chemotherapy in pediatric acute lymphoblastic leukemia

Journal

PEDIATRIC BLOOD & CANCER
Volume 69, Issue 6, Pages -

Publisher

WILEY
DOI: 10.1002/pbc.29467

Keywords

acute lymphoblastic leukemia; ALL; hypoglycemia; treatment-related adverse events

Funding

  1. National Heart, Lung, and Blood Institute [K01HL143153]
  2. National Institute of Diabetes and Digestive and Kidney Diseases [R01DK056268, T32DK063688]
  3. National Institute of Neurological Disorders and Stroke [T32NS091006]
  4. National Cancer Institute [K07CA211956]

Ask authors/readers for more resources

This study found a high incidence of hypoglycemia during maintenance chemotherapy, with younger age at maintenance initiation and hepatotoxicity during chemotherapy prior to maintenance initiation being associated with this outcome. It highlights the importance of counseling and monitoring for hypoglycemia, especially in young children.
Background Fasting hypoglycemia is a recognized occurrence among pediatric patients with acute lymphoblastic leukemia (ALL) during maintenance therapy. Existing publications describing this finding are limited to small studies and case reports. Our objective was to determine the incidence of hypoglycemia during maintenance chemotherapy and to investigate the association of age, as well as other potential risk factors, with this outcome in pediatric patients with ALL. Procedure This retrospective cohort study included individuals 1 to 21 years of age with ALL treated with antimetabolite-containing maintenance chemotherapy at a large children's hospital between January 2011 and December 2014. The primary endpoint was time to first documented episode of hypoglycemia during maintenance therapy, defined as single measurement of plasma glucose We identified 126 eligible patients, of whom 63% were documented as White, non-Hispanic, 28% as non-White, non-Hispanic, and 9% as Hispanic. Twenty-eight children (22%) had documented hypoglycemia during maintenance therapy. Younger age at the start of maintenance and hepatotoxicity documented during chemotherapy prior to maintenance initiation were associated with hypoglycemia (adjusted HR age = 0.88; 95% CI, 0.78-0.99; adjusted HR prior hepatotoxicity = 3.50; 95% CI, 1.47-8.36). Conclusions Nearly one quarter of children in our cohort had hypoglycemia documented during maintenance chemotherapy. Younger age at maintenance initiation and hepatotoxicity during chemotherapy prior to maintenance initiation emerged as risk factors. These findings highlight the importance of counseling about the risk of, and monitoring for, hypoglycemia, particularly in young children.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available